Biopolym. Cell. 2024; 40(4):288-297.
http://dx.doi.org/10.7124/bc.000B04
Molecular Biomedicine
The IAP Inhibitor GDC-0152 Suppresses Cell Proliferation and Induces Apoptosis in Colon Cancer Cell Lines
1Özdemir D., 1Göksu S., 2Baydas G., 3Tykhomyrov A. O., 1Ağca C. A.
  1. Bingöl University
    Selahaddin-i Eyyubi Mah, Üniversite Cad, No: 1, Bingöl, Türkiye, 12000
  2. Altınbaş University
    Mahmutbey Dilmenler Cad, No:26, İstanbul, Türkiye, 34218
  3. O. V. Palladin Institute of Biochemistry, NAS of Ukraine
    9, Leontovycha Str., Kyiv, Ukraine, 01054

Abstract

Aim. The present study was aimed to explore the impact of inhibitor of apoptosis protein (IAP) small molecule inhibitor GDC-0152 on colon cancer cells (HCT-116 and HT-29). Methods. The effects of GDC-0152 on colon cancer cells, cell viability, and proliferation were assessed using WST-1 assay and Real Time Cell Analysis System (xCELLigence), while apoptosis was detected using AO/EBr staining and Annexin V/Flow cytometry assays. The expression of XIAP were analyzed using western blotting analysis. Results. It was shown that GDC-0152 can inhibit the proliferation and clonogenic potential of colon cancer cells. We used a viability assay to demonstrate that GDC-0152 inhibited cell growth with IC50 values 28,90 μM in HCT-116, and 24,32 μM in HT-29. A wound healing assay showed that GDC-0152 inhibited migration of colon cancer cells. Further validation found that GDC-0152 induced apoptosis in colon cancer cells. Conclusions. Taken together, our results suggest that GDC-0152 suppressed the CC cell proliferation, migration, and induces apoptosis in a concentration-dependent manner. In conclusion, GDC-0152, a IAP inhibitor, can be considered as a valid approach to target cell death in colon cancer.
Keywords: GDC-0152, inhibitors of apoptosis (IAPs), colorectal cancer, apoptosis
Full text: (PDF, in English)

References

[1] Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1):22.
[2] Khan SZ, Lengyel CG. Challenges in the management of colorectal cancer in low- and middle-income countries. Cancer Treat Res Commun. 2023; 35:100705.
[3] Cong H, Xu L, Wu Y, Qu Z, Bian T, Zhang W, Xing C, Zhuang C. Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives. J Med Chem. 2019; 62(12):5750-72.
[4] McCann C, Matveeva A, McAllister K, Van Schaeybroeck S, Sessler T, Fichtner M, Carberry S, Rehm M, Prehn JHM, Longley DB. Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer. FEBS J. 2021; 288(18):5374-88.
[5] Cossu F, Milani M, Mastrangelo E, Lecis D. Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment. Comput Struct Biotechnol J. 2019; 17:142-50.
[6] Mace PD, Shirley S, Day CL. Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ. 2010; 17(1):46-53.
[7] Cetraro P, Plaza-Diaz J, MacKenzie A, Abadía-Molina F. A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer. Cancers (Basel). 2022; 14(7):1671.
[8] Silke J, Meier P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb Perspect Biol. 2013; 5(2):a008730.
[9] Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010; 430(2):199-205.
[10] Dumétier B, Zadoroznyj A, Berthelet J, Causse S, Allègre J, Bourgeois P, Cattin F, Racoeur C, Paul C, Garrido C, Dubrez L. cIAP1/TRAF2 interplay promotes tumor growth through the activation of STAT3. Oncogene. 2023; 42(3):198-208.
[11] Crawford N, Stott KJ, Sessler T, McCann C, McDaid W, Lees A, Latimer C, Fox JP, Munck JM, Smyth T, Shah A, Martins V, Lawler M, Dunne PD, Kerr EM, McDade SS, Coyle VM, Longley DB. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. Mol Cancer Ther. 2021; 20(9):1627-39.
[12] Hehlgans S, Oppermann J, Reichert S, Fulda S, Rödel C, Rödel F. The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. Radiat Oncol. 2015; 10:198.
[13] Güllülü Ö, Hehlgans S, Rödel C, Fokas E, Rödel F. Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer-A Promising Signaling Network for Therapeutic Interventions. Cancers (Basel). 2021; 13(4):624.
[14] Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, Halladay J, Hymowitz SG, La H, LoRusso P, Maurer B, Murray L, Plise E, Quan C, Stephan JP, Young SG, Tom J, Tsui V, Um J, Varfolomeev E, Vucic D, Wagner AJ, Wallweber HJ, Wang L, Ware J, Wen Z, Wong H, Wong JM, Wong M, Wong S, Yu R, Zobel K, Fairbrother WJ. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012; 55(9):4101-13.
[15] Hu R, Li J, Liu Z, Miao M, Yao K. GDC-0152 induces apoptosis through down-regulation of IAPs in human leukemia cells and inhibition of PI3K/Akt signaling pathway. Tumour Biol. 2015; 36(2):577-84.
[16] Shekhar TM, Burvenich IJG, Harris MA, Rigopoulos A, Zanker D, Spurling A, Parker BS, Walkley CR, Scott AM, Hawkins CJ. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice. BMC Cancer. 2019; 19(1):924.
[17] Tchoghandjian A, Soubéran A, Tabouret E, Colin C, Denicolaï E, Jiguet-Jiglaire C, El-Battari A, Villard C, Baeza-Kallee N, Figarella-Branger D. Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death Dis. 2016; 7(8):e2325.
[18] Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound Healing Assay. J Invest Dermatol. 2017; 137(2):e11-e16.
[19] Agca CA, Kırıcı M, Nedzvetsky VS, Gundogdu R, Tykhomyrov AA. The Effect of TIGAR Knockdown on Apoptotic and Epithelial-Mesenchymal Markers Expression in Doxorubicin-Resistant Non-Small Cell Lung Cancer A549 Cell Lines. Chem Biodivers. 2020; 17(9):e2000441.
[20] Lin IL, Lin YT, Chang YC, Kondapuram SK, Lin KH, Chen PC, Kuo CY, Coumar MS, Cheung CHA. The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells. Toxicol Appl Pharmacol. 2024; 485:116888.
[21] Dumétier B, Zadoroznyj A, Dubrez L. IAP-Mediated Protein Ubiquitination in Regulating Cell Signaling. Cells. 2020; 9(5):1118.
[22] Ding R, Wang X, Chen W, Li Z, Wei AL, Wang QB, Nie AH, Wang LL. WX20120108, a novel IAP antagonist, induces tumor cell autophagy via activating ROS-FOXO pathway. Acta Pharmacol Sin. 2019; 40(11):1466-79.
[23] Yang L, Shu T, Liang Y, Gu W, Wang C, Song X, Fan C, Wang W. GDC-0152 attenuates the malignant progression of osteosarcoma promoted by ANGPTL2 via PI3K/AKT but not p38MAPK signaling pathway. Int J Oncol. 2015; 46(4):1651-8.
[24] Zhang B, Yang C, Wang R, Wu J, Zhang Y, Liu D, Sun X, Li X, Ren H, Qin S. OTUD7B suppresses Smac mimetic-induced lung cancer cell invasion and migration via deubiquitinating TRAF3. J Exp Clin Cancer Res. 2020; 39(1):244.